Myelofibrosis Treatment and the Unmet Need
Myelofibrosis (MF) is a severe and progressive cancer in which mutant hematopoietic stem/progenitor blood cell clones cause fibrosis and scarring of bone marrow. It is a chronic inflammatory condition in which megakaryocytes secrete inflammatory cytokines and growth factors that pathologically destroy bone marrow, impairing hematopoiesis. Median survival post-diagnosis is approximately 5 years.
There are over 50,000 patients diagnosed with MF in US, EU and Japan many of which have a poor quality of life owing to chronic fatigue, anemia, pain, itching, fever and night sweats. There remains a high unmet need for alternative disease-modifying therapies that improve symptom management.